 The lung cancer drug did not significantly prolong survival in patients with the disease. Meanwhile, another of its major money spinners - cholesterol drug Crestor - is facing mounting safety concerns. AstraZeneca had hoped to pitch its Iressa drug against rival medicine Tarceva. But Iressa proved no better than a placebo in extending lives in the trial involving 1,692 patients. John Patterson will be in charge of drug development.